Showing 4931-4940 of 10632 results for "".
- New Class of Immunotherapy Drugs May Fight Melanomahttps://practicaldermatology.com/news/new-class-of-immunotherapy-drugs-may-fight-melanoma/2461682/A new class of immunotherapy shows promising results for fighting melanoma, a new study shows. The study, published in Nature Communications by researchers from King’s College London and Guy’s and St Thomas’ NHS Foundation Trust, investigates whether a n
- Garnier Nutrisse Announces Drew Barrymore as Brand Ambassadorhttps://practicaldermatology.com/news/garnier-nutrisse-announces-drew-barrymore-as-brand-ambassador/2461577/Drew Barrymore is the new brand ambassador for Garnier Nutrisse, an expansion to her current role with the Garnier portfolio. Barrymore's role debuts with a creative campaign highlighting Garnier Nutrisse's new and improved Nourishing Color Crème formula for nourished hai
- FDA Gives Nod to First Particulate Placental Extracellular Matrix Medical Device for Wound Managementhttps://practicaldermatology.com/news/fda-gives-nod-to-first-particulate-placental-extracellular-matrix-medical-device-for-wound-management/2461574/The U.S. Food and Drug Administration cleared Convatec’s InnovaMatrix PD particulate placental extracellular matrix medical device for wound management. The InnovaMatrix PD medical device joins Convatec’s existing InnovaMatrix AC product as the first and only next-gener
- Daniel Hopkins Named New CEO at AlumierMDhttps://practicaldermatology.com/news/daniel-hopkins-named-new-ceo-at-alumiermd/2461537/Daniel Hopkins is AlumierMD’s new Chief Executive Officer. With more than a decade of experience in the aesthetic sector, Mr. Hopkins is prepared to take AlumierMD's commitment to the global aesthetic community through its next exciting phase of growth. Mr. Hopkins
- Enrollment Complete for Journey’s Phase 3 Trials of DFD-29 in Papulopustular Rosaceahttps://practicaldermatology.com/news/enrollment-complete-for-journeys-in-phase-3-trials-of-dfd-29-in-papulopustular-rosacea/2461492/Journey Medical Corporation’s Phase 3 clinical trial program of DFD-29 for papulopustular rosacea is now fully enrolled. The Phase 3 clinical trials are part of a collaboration with Dr. Reddy’s Laboratories Ltd. for the ongoing development and commercialization of the D
- Hydrafacial, DOCTOR BABOR Collab for New Collagen HA Boosterhttps://practicaldermatology.com/news/hydrafacial-doctor-babor-collab-for-new-collagen-ha-booster/2461461/The Beauty Health Company’s Hydrafacial launched a new booster co-created with BABOR Skincare. The new DOCTOR BABOR Collagen HA booster is inspired by DOCTOR BABOR’s formulations and developed with the BABOR Laboratories in Germany. “Hydrafacial has cre
- FDA Clears LASEROPTEK's HELIOS IV-785 for Aesthetic and Medical Dermatology Usehttps://practicaldermatology.com/news/fda-clears-laseropteks-helios-iv-785-for-aesthetic-and-medical-dermatology-use/2461326/The U.S. Food and Drug Administration has granted 510(k) clearance to LASEROPTEK Co., Ltd.’s HELIOS IV-785 laser system for aesthetic and medical dermatology applications. HELIOS IV-785's novel and synergistic combination of 785nm picosecond photoacoustic effect and 1064 &
- Health Canada Clears Cutera’s AviClearhttps://practicaldermatology.com/news/health-canada-clears-cuteras-aviclear/2461268/Health Canada has cleared Cutera, Inc.’s AviClear for the treatment of mild, moderate, and severe acne. This Health Canada announcement comes on the heels of the U.S. Food and Drug Administration’s 510(k) clearance of AviClear, in March 2022. In addition
- Crown to Acquire Aesthetic Product Portfolio from Eclipsehttps://practicaldermatology.com/news/crown-to-acquire-aesthetic-product-portfolio-from-eclipse/2461208/Crown Laboratories will acquire the global aesthetics-focused assets of Eclipse. The acquisition expands Crown's aesthetics' product portfolio and enhances Crown's overall value proposition as a global leader in science-based aesthetic skincare solutions. "We
- FDA Issues Complete Response Letter for UCB's Bimekizumabhttps://practicaldermatology.com/news/fda-issues-complete-response-letter-for-ucbs-bimekizumab/2461195/There’s a delay in the US regulatory review of UCB’s bimekizumab for the treatment of adults with moderate to severe plaque psoriasis. FDA has indicated it cannot approve the BLA for bimekizumab in its current form. The agency issued a Complete Response Letter (CRL) that sta